BTIG initiated coverage of Connect Biopharma with a Buy rating and $10 price target. The firm believes rademikibart is "set up to thrive" in the acute settings of both indications of asthma and chronic obstructive pulmonary disorder, supported by its unusually fast and best-in-class onset of effect, the analyst tells investors.
